98%
921
2 minutes
20
Unlabelled: Gestational diabetes mellitus (GDM) is a known risk factor for both maternal and fatal complications. Glycemic control in pregnant women is important for preventing these complications. However, the need for insulin therapy in pregnant women is difficult to determine. This study focuses on glucagon, which provides new prospects due to advancement in the measurement assay method for type 2 diabetes. Investigating the dynamics of glucagon in pregnant women will help in the diagnosis of GDM and in identifying those requiring insulin treatment. A total of 58 pregnant women between 24 and 31 weeks of gestation underwent a 75-g glucose tolerance test at our institution between 2013 and 2015. The results showed differences in post-glucose and insulin levels between patients with and without GDM, but not in glucagon levels. However, differences were observed in fasting plasma glucose (79.2 ± 4.2 vs. 85.7 ± 8.5 mg/dL, P = 0.006) and in the glucagon change rates at 15, 30, and 60 min after glucose loading between patients with GDM requiring insulin treatment and those who did not. Using a cutoff value of -0.4566 for the glucagon change rate at 60 min as the predictor for insulin treatment, the sensitivity and specificity were 63.16% and 92.31%, respectively. Overall, the measurement of glucagon during the early post-glucose load period may be useful in predicting insulin therapy requirements in pregnant Asian women with GDM.
Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-025-00797-y.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954775 | PMC |
http://dx.doi.org/10.1007/s13340-025-00797-y | DOI Listing |
BJOG
September 2025
Department of Obstetrics and Gynaecology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Objective: To estimate the effect on healthcare resource use after introducing the World Health Organization diagnostic criteria (WHO-2013) for gestational diabetes mellitus (GDM) compared to former criteria in Sweden (SWE-GDM).
Design: A cost-analysis alongside the Changing Diagnostic Criteria for Gestational Diabetes (CDC4G) randomised controlled trial.
Setting: Sweden, with risk-factor based screening for GDM.
Thorax
September 2025
Usher Institute, The University of Edinburgh, Edinburgh, UK
Background: The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available for prevention of severe RSV-associated disease in 2023. While clinical trials showed good efficacy and safety, their restrictive inclusion criteria, small sample sizes and short follow-up limit generalisability. We aimed to summarise real-world evidence on the effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults.
View Article and Find Full Text PDFVaccine
September 2025
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Background: Among pregnant and postpartum women, decision-making for receiving the COVID-19 vaccine is influenced by vaccine safety concerns, misconceptions, shifting vaccine policies, and exclusion in the initial vaccine rollout. This caused confusion and vaccine hesitancy among many groups including pregnant and postpartum women.
Objective: The objective of this study was to understand the multilevel factors that influence vaccine decision-making among pregnant and postpartum women in Pakistan, which is crucial for improving vaccine demand among the vulnerable group-pregnant and postpartum women.
Rev Med Interne
September 2025
Service de médecine interne, centre hospitalier universitaire de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France; Université de médecine et de pharmacie, université de Poitiers, Poitiers, France; Inserm U1313, université de Poitiers, Poitiers, France.
Introduction: Many women of childbearing age are being treated for chronic conditions that require long-term medication. We assessed the knowledge of women being treated in internal medicine and clinical immunology, regarding the impact of their disease and specific treatments on a potential pregnancy.
Methods: Between September 1st, 2019, and November 1st, 2020, in four hospitals in the Poitou-Charentes region, a questionnaire was given to every woman aged 18 to 44 who came in for an internal medicine and clinical immunology consultation for the follow-up of a chronic systemic disease.
Vox Sang
September 2025
Blood Group Genetics Laboratory, Irish Blood Transfusion Service, Dublin, Ireland.
Background And Objectives: The discovery of circulating fetal DNA in maternal plasma enabled non-invasive prenatal testing (NIPT) for targeted anti-D prophylaxis. In 2019, Ireland implemented an in-house test to guide this care. Here, we report 6 years of service.
View Article and Find Full Text PDF